Summary:
We sought to assess if leaving in place a previously inserted noncolonized or infected implantable catheter (IC) is associated with an increase in morbidity in patients undergoing autologous peripheral stem cell transplantation (APSCT). Medical records from all patients between March 1997 and January 2002 undergoing APSCT with an IC in place were reviewed. Case group (IC in place) was compared with a control group (no IC) from 6 days prior to 60 days after APSCT. In all, 43 cases were matched with 43 controls by underlying disease, age and sex. In both groups, duration of neutropenia and use of antimicrobial prophylaxis were comparable. Underlying malignancies were lymphoma (22/24), multiple myeloma (14/12), leukemia (3/3), and others (7/7) in case and control groups. Cases and controls had comparable rates of risk for fever, bloodstream infection, use of vancomycin and amphotericin B, and death, as well as comparable lengths of stay and readmissions. ICs were used in 20 of 43 patients. Using the IC did not significantly increase the risk of fever, bloodstream infection, length of stay, and/or readmissions after APSCT but was associated with increased use of antibacterial and antifungal agents. Leaving in place a previously inserted, noncolonized or infected IC did not increase morbidity in patients undergoing APSCT. [1] [2] [3] However, one of the most serious complications of these intravascular devices is infection, particularly among patients with cancer. 4, 5 The accumulation of infected clots under the silicone septum of the reservoir has been reported as the source for IC-related bloodstream infections. 6 The Foundation for the Fight against Leukemia (FUN-DALEU) is a national referral center for patients receiving autologous peripheral stem cell transplantation (APSCT) who come from all areas of Argentina. Some of these referred patients already have an IC in place by the time of their first evaluation at our institution. We hypothesized that these ICs might be a potential source of infection after APSCT because most of these ICs have been placed a long time before transplantation, at a different institution, under unknown aseptic techniques, and there is uncertainty regarding the type of care that the IC and the patient received. While the policy of some institutions in our country is to remove the IC prior to APSCT, our policy has been to remove only those ICs that show colonization or infection prior to APSCT. However, there are no data regarding the morbidity associated with any of these strategies.
The purpose of the current study was to assess whether leaving in place a previously inserted IC, which is not colonized or infected, is associated with an increase in morbidity in patients undergoing APSCT.
Patients and methods
This retrospective study was conducted at FUNDALEU in Buenos Aires, Argentina, between March 1997 and January 2002. This study was approved by the Institutional Teaching and Research Committee.
Patients
Medical records of patients transplanted during the study period were reviewed. Two groups of patients were identified: a case group in which all patients had an IC in place at the time of transplantation and a control group in which patients did not have an IC in place at the time of transplantation.
Patients from both groups were matched (1:1) by age, sex, and underlying hematological malignancy. All patients underwent placement of a percutaneous central venous catheter (CVC) for transplantation and management of subsequent complications. In patients from the case group, the IC was left in place but was not used during the hospital admission for APSCT unless it was necessary (eg, patients who needed venous access after the percutaneous catheter had to be removed). All ICs left in place were shown to be free of infection or colonization by clinical assessment and by a negative qualitative blood culture drawn through the IC within 20 days prior to transplantation.
Blood cultures drawn through the IC
Blood cultures were drawn, by two nurses, using aseptic techniques (sterile gloves and masks). Following skin disinfection with povidone-iodine, a Huber needle was inserted and 5 ml of blood was aspirated. Later, the IC was flushed with a heparin saline solution (500 IU heparin in 2 ml of saline solution), and the Huber needle was removed. Blood cultures were processed according to conventional methods. 7 Blood specimens were collected in commercially prepared bottles containing trypticase soy broth enriched with yeast extract, sodium polyanethol-sulfonate, hemin, and cystine (Britania s , Buenos Aires, Argentina). Blood cultures were incubated at 351C for 14 days. Subcultures were made onto chocolate blood agar plates (incubated at 351C in a carbon dioxide atmosphere) and MacConkey agar (in case of presence of gram-negative bacteria).
We assumed that a negative blood culture obtained through the IC was a good indicator of absence of IC colonization or infection. Although we could find no data confirming this hypothesis for this type of catheter, data from cancer patients with percutaneous and tunneled central venous catheters have shown that when a blood culture taken through the central venous line is negative, the likelihood ratio of catheter tip colonization is low (0.7%). 8 All patients were followed from 6 days before, to 60 days after, APSCT.
Catheter care
At our institution, all CVCs are maintained by specially trained nurses using standard procedures. The ICs are flushed with a heparin saline solution (500 IU heparin in 2 ml saline solution) every 28 days. When the IC is used after transplantation, the Huber needle is changed every 7 days according to aseptic techniques. 4 When placement of the IC has been performed outside of our institution, information regarding the type of catheter care that patients received from the time of catheter placement until arrival at our institution for APSCT is not available.
Clinical management
All patients received prophylaxis against herpes simplex virus reactivation with intravenous acyclovir (5 mg/kg twice per day) or oral valacyclovir (500 mg twice per day). In addition, patients with acute myeblastic leukemia receiving the conditioning regimen that included busulfan plus cyclophosphamide or those with solid organ tumors (other than breast cancer) receiving conditioning that included ifosfamide plus carboplatin and etoposide also received prophylaxis against gram-negative bacilli (norfloxacin 400 mg twice per day PO) and systemic candidiasis (fluconazole 200 mg once daily) from 3 days prior to APSCT until recovery from neutropenia (absolute neutrophil count [ANC]41000/ml) or development of infection.
All febrile and neutropenic patients started antibiotic treatment with cefepime or piperacillin-tazobactam. Vancomycin was added in any of the following conditions: (a) shock; (b) persistent fever despite the empiric treatment mentioned above; (c) documented infection by methicillinresistant Staphylococci; or (d) when the skin or the CVC was suspected to be the source of the infection. Antifungal treatment with amphotericin B was started in the setting of (a) persistent fever (45 days) despite broad-spectrum antibiotics that included a glycopeptide; (b) radiologic evidence of a probable mold infection; or (c) documented invasive fungal infection.
Patients were considered to have IC-related bacteremia when peripheral blood cultures and a segment of the IC (tip or reservoir) yielded the same microorganism (same species, same susceptibility). 9 When the IC was removed, the tip and the membrane of the reservoir were cultured using the quantitative (vortex) method. 10, 11 The membrane was removed from the reservoir under sterile technique for culture in the microbiology lab. The debris of the internal lumen of the reservoir was not cultured.
Morbidity end points
End points studied as markers of morbidity within the 60-day period after APSCT included occurrence of fever and bloodstream infection; use of vancomycin and amphotericin B; duration of antibiotic therapy; number of readmissions; days of stay during first admission and during subsequent readmissions; and occurrence of death.
Statistical analyses
The Wilcoxon signed-rank and Student's t-tests were used to assess differences between groups for two variables. The Yates corrected w 2 , Fisher's exact, or Wilk's (log likelihood ratio) tests were used for dichotomous variables. To estimate the multivariable predictive value of several independent covariates, one stepwise multiple logistic regression model was used. Data are expressed as mean7standard deviation. Values for Pp0.05 were accepted as statistically significant. CSS/Statistical, 5.1 (Statsoft Corp. Tulsa, Okla, USA) and Epi Info v. 5, 1990 were used for statistical analyses.
Results
In all, 43 patients (IC group) were matched with 43 controls (no IC). Patients from both groups had comparable antimicrobial prophylaxis and duration of neutropenia (Table 1) .
All ICs were inserted before APSCT, mean time 222 days (range, 16-1237). In all, 31 (72%) ICs had been placed in different institutions, while only 10 (23%) had been placed in our institution. Data were not available for two (5%) ICs.
The end points studied as morbidity markers in the IC and control group are shown in Table 2 . A one-stepwise multiple logistic regression model was used, including the variables age, sex, underlying disease, duration of neutropenia, IC in place, and antibacterial and antifungal prophylaxis. In this model, lack of antibacterial prophylaxis increased the risk of fever (OR: 0.199 (95% CI: 0.059, 0.669), P ¼ 0.0091). The presence of the IC in place did not increase the risk of fever, bloodstream infections, or death; use of vancomycin or amphotericin B; the number of days of antibiotic use or hospital stay; or the number of readmissions. Similar results were found regardless of the institution at which the IC had been placed (data not shown). Among the bloodstream infections observed in the case group, none was considered to be related to the IC. However, 1 patient had the IC removed and therefore, the reservoir and tip could not be cultured.
Within the 60-day period after APSCT, 20 of 43 patients required use of their IC. Most ICs were accessed within the first 20 days of the transplantation (mean, day þ 7, range À6 to þ 18) and were in use for an average of 9 days (range, 1-41 days). Of the patients, 55% (11 of 20) were neutropenic at the time of IC access. One of the 20 patients developed S. aureus bacteremia, and the IC was removed. However, the membrane of the reservoir culture was negative, and the bacteremia were not considered to be related to the IC. Therefore, the case group (IC group) can be divided in two subgroups: patients who used the IC (IC-U) (n ¼ 20) and patients who did not use it (IC-NU) (n ¼ 21). Data were not available for this analysis for two patients.
We hypothesized that using the IC might have a greater association with increased morbidity than having the IC in place without using it. We then analyzed the markers of morbidity in the IC-U vs the IC-NU groups (Table 3) . Risk of fever, use of vancomycin and amphotericin B, overall length of stay, and number of readmissions were comparable in both groups.
The frequency of bloodstream infections tended to be higher in the IC-U group (7/20, 35%) than in the IC-NU Within the 60-day period after APSCT, three ICs had to be removed: one owing to Staphylococcus aureus bacteremia (mentioned above) and two owing to patient death.
Discussion
To our knowledge, this is the first study to demonstrate that patients with a previously inserted, noncolonized or infected IC in place at the time of APSCT have the same morbidity as patients undergoing transplantation without an IC in place. Specifically, the presence of the IC did not increase the risk of fever, bloodstream infections, or death; the use of vancomycin or amphotericin B; number of days of antibiotic use or hospital stay; and number of readmissions.
We also showed that using the IC during the transplant period did not significantly increase the risk of fever or bloodstream infections, the use of empirical amphotericin B and vancomycin, the overall length of stay, and the number of readmissions. However, there was a tendency toward a higher frequency of bloodstream infections among patients who used the IC within 60 days of the APSCT. We suggest that while the presence of the IC is not a risk factor for increased morbidity, the use of the IC is. This use makes these ICs comparable to percutaneous CVCs in which the rate of infection increases with time, probably because prolonged catheterization is associated with more hub manipulation and increased intraluminal colonization. 12 ICs have been available since 1982. 1, 2 The main complications associated with ICs are thrombosis and infection. Maintenance measures are directed at preventing these complications and include regular flushing with heparin, and aseptic techniques for insertion, wound care, needle placement, site care, and tube handling. 9 The compliance for these maintenance measures varies from patient to patient and from one institution to another. The APSCT is associated with a period of high risk for bleeding and infection due to neutropenia and thrombocytopenia. 13 Many of our referred patients showed evidence that procedures for catheter care had not been strictly adhered to, and we therefore consider these patients as being at high risk for catheter-related infection during the APSCT period. To prevent such infections, some centers in our country remove all ICs prior to transplantation. We designed a more conservative policy in which every APSCT patient with an IC in place has a blood culture taken through the IC within 20 days of transplantation. The IC is removed if the blood culture is positive. In this study, we showed that this policy is safe.
We found no published information regarding the presence of a foreign body (IC, IUD, etc.) in the setting of transplantation and its impact on morbidity.
The possible limitations of our study are its retrospective nature, its small size, and short follow-up. In addition, because we do not have information regarding catheter care before arrival at our institution, we could not assess if patients with ICs placed at some other institutions were at higher risk of infection than others. Also, we do not know if keeping in place a colonized IC (positive blood culture taken through the IC) would modify morbidity.
In conclusion, this is the first study to suggest that recipients of APSCT who have a noncolonized or infected IC in place have the same morbidity as patients who do not have an IC in place. However, use of the IC during 60 days after APSCT may increase the empirical use of antifungal or antibacterial agents.
